Acadia Pharmaceuticals Inc 8-K Filing
Ticker: ACAD · Form: 8-K · Filed: Nov 5, 2025 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Acadia Pharmaceuticals Inc (ticker: ACAD) to the SEC on Nov 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar).
How long is this filing?
Acadia Pharmaceuticals Inc's 8-K filing is 2 pages with approximately 531 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-11-05 16:13:31
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20251105.htm (8-K) — 45KB
- acad-ex99_1.htm (EX-99.1) — 279KB
- 0001193125-25-266959.txt ( ) — 443KB
- acad-20251105.xsd (EX-101.SCH) — 24KB
- acad-20251105_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 5, 2025, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated November 5, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Acadia Pharmaceuticals Inc. Date: November 5, 2025 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary